Alex Berg*, Ryan P. Mayers*, and Sarah Richards*
Edited by Sharon Jiang and Friederike M. C. Benning
Article | Aug. 29 2022
*Emails: firstname.lastname@example.org, email@example.com, firstname.lastname@example.org
- The recent approval of Aduhelm, a medicine indicated for Alzheimer’s disease, sparked controversy in part due to reliance on biomarkers instead of primary data showing cognitive improvement
- The use of biomarker surrogate endpoints enables medicines to make it from bench to bedside faster but reduces the certainty that these medicines show clinical efficacy
- Future policy should build on the lessons from the Aduhelm approval, consider how biomarkers are chosen, and balance the risk of using biomarkers with their potential benefit to patients with neurodegenerative diseases
This MIT Science Policy Review article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/ by/4.0/.